pm359
pm359: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Prime Medicine, Inc. (PRME) | Phase 1/Phase 2 |
Clinical Trials (1)
A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Modified Ex Vivo Using Prime Editing (PM359) in Participants With Autosomal Recessive Chronic Granulomatous Disease Due to Mutations in the NCF1 Gene
Frequently asked questions
Who is developing pm359?
pm359 is being developed by Prime Medicine, Inc..
How many clinical trials involve pm359?
BioSniper tracks 1 clinical trial involving pm359.
Get deeper analysis on pm359
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis